| Entries |
| Document | Title | Date |
|---|
| 20080206269 | Bacterial pheromones and uses thereof - RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described | 08-28-2008 |
| 20080213294 | Immunization of dairy cattle with GapC protein against streptococcus infection - The GapC plasmin binding protein genes of | 09-04-2008 |
| 20080220010 | Immunogenic Compositions for Streptococcus Agalactiae - This application relates to Group B | 09-11-2008 |
| 20080241180 | Liquid Vaccines For Multiple Meningococcal Serogroups - Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135. | 10-02-2008 |
| 20080241181 | Environmentally regulated genes of Streptococcus suis - The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a | 10-02-2008 |
| 20080241182 | MYCOBACTERIUM TUBERCULOSIS PERSISTANCE GENES - Compositions and methods for preventing | 10-02-2008 |
| 20080248056 | Immunomodulatory Product Obtained from a Bifidobacterium Culture and Compositions Containing the Same - The invention relates to an immunomodulatory product obtained from a | 10-09-2008 |
| 20080260767 | Novel Protein Which can be Used, in Particular, for the In Vitro Isolation and Prevention of Legionella Pneumophila Infections - The invention relates to novel polynucleotides, including SEQ ID NO: 1 or parts or variants of the sequence, novel polypeptides encoded by the polynucleotides, expression vectors including the polynucleotides and host cells including the expression vectors. The polynucleotides and polypeptides can be used in the field of in vitro diagnosis and/or for production of vaccines against | 10-23-2008 |
| 20080260768 | Streptococcus pneumoniae proteins and nucleic acid molecules - Protein antigens from | 10-23-2008 |
| 20080267990 | TB DIAGONOSTIC BASED ON ANTIGENS FROM M. TUBERCULOSIS - The present invention is based on the identification and characterization of a number of novel | 10-30-2008 |
| 20080279880 | PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A | 11-13-2008 |
| 20080299142 | COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a | 12-04-2008 |
| 20080305124 | ORAL PERTUSSIS VACCINE AND METHOD FOR PRODUCING PERTUSSIS VACCINE - The present invention is related to an oral pertussis vaccine and a method for producing pertussis vaccine, wherein the oral pertussis vaccine comprises amino acid sequence of 1094 to 1279 (SEQ ID NO.1) of filamentous hemagglutinin. The method for producing pertussis vaccine comprises following steps: constructing a vector comprising amino acid sequence of 1094 to 1279 (SEQ ID NO. 1) of filamentous hemagglutinin; transforming the vector into | 12-11-2008 |
| 20080305125 | Mutant Forms Of EtxB and CtxB And Their Use As Carriers - The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB. | 12-11-2008 |
| 20080311144 | MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule. | 12-18-2008 |
| 20080311145 | PROTEIN CAGE IMMUNOTHERAPEUTICS - The present invention provides compositions of heat shock protein cages for use in therapeutic vaccines. The heat shock protein cages of the invention have attached antigen, located either on the interior or exterior of the protein cage, and optionally an adjuvant. | 12-18-2008 |
| 20080311146 | Immunogenic Composition - The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain. | 12-18-2008 |
| 20090004217 | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) - antigens that can be used to differentiate | 01-01-2009 |
| 20090010956 | EHRLICHIA EWINGII PROTEINS, NUCLEIC ACIDS, AND METHODS OF THEIR USE - The novel omp-1 gene cluster encoding twenty one | 01-08-2009 |
| 20090010957 | Immunogenic Mycoplasma Hyopneumoniae Polypeptides - polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing | 01-08-2009 |
| 20090017054 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from | 01-15-2009 |
| 20090022753 | Surface proteins of streptococcus pyogenes - β-hemolytic streptococci polynucleotides, polypeptides, particularly | 01-22-2009 |
| 20090022754 | Recombinant antigen for diagnosis and prevention of murine typhus - The invention relates to a recombinant immunogenic composition from | 01-22-2009 |
| 20090022755 | VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of | 01-22-2009 |
| 20090022756 | Recombinant F1-V Plague Vaccine - Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of | 01-22-2009 |
| 20090028891 | Chlamydia Antigens and Uses Thereof - The invention provides protein and nucleic acid sequences of | 01-29-2009 |
| 20090041796 | Surface protein of leptospira - The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods. | 02-12-2009 |
| 20090041797 | MODIFIED TOXINS - The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease. | 02-12-2009 |
| 20090053258 | Assays for diagnosis of tuberculosis and uses thereof - The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines. | 02-26-2009 |
| 20090053259 | VACCINES AND METHODS FOR TREATMENT OR PREVENTION OF GRAM NEGATIVE BACTERIAL INFECTION IN A VERTEBRATE SUBJECT - Methods for the treatment or prevention of Gram negative bacterial infection in a vertebrate subject are provided. The methods provide administering an antagonist of bacterial flagellar protein biosynthesis to the vertebrate subject in an amount effective to reduce or eliminate the bacterial infection. Methods for the treatment or prevention of | 02-26-2009 |
| 20090060932 | Groups Of Borrelia Burgdorferi And Borrelia Afzelii That Cause Lyme Disease In Humans - The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing | 03-05-2009 |
| 20090060933 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 03-05-2009 |
| 20090060934 | S. AGALACTIAE ANTIGENS I & II - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 03-05-2009 |
| 20090068216 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 03-12-2009 |
| 20090068217 | Recombinant vaccine for preventing and treating porcine atrophic rhinitis - Disclosed is a recombinant vaccine for porcine atrophic rhinitis. A vaccine is provided which uses a | 03-12-2009 |
| 20090068218 | Antigens for Vaccination Against and Detection of Mycoplasma Suis - The present invention relates to antigens for vaccination against and detection of | 03-12-2009 |
| 20090074806 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from | 03-19-2009 |
| 20090074807 | MORAXELLA (BRANHAMELLA) CATARRHALIS ANTIGENS - The present invention relates to polypeptides of | 03-19-2009 |
| 20090074808 | Secreted Streptococcus Pneumoniae Proteins - Novel proteins from | 03-19-2009 |
| 20090092629 | VACCINE FOR NONTYPEABLE HAEMOPHILUS INFLUENZAE INFECTION - This invention provides a method for identifying strains of nontypeable | 04-09-2009 |
| 20090104218 | Group B Streptococcus - Polypeptides and nucleic acids from | 04-23-2009 |
| 20090110691 | Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - The invention provides | 04-30-2009 |
| 20090117142 | RECOMBINANT FUSOBACTERIUM NECROPHORUM LEUKOTOXIN VACCINE AND PREPARATION THEREOF | 05-07-2009 |
| 20090117143 | Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens - An immunogenic composition comprising a recombinant protein comprising a | 05-07-2009 |
| 20090123491 | Novel method for preventing or treating M tuberculosis infection - The present invention is directed to methods of preventing reactivation of active and latent | 05-14-2009 |
| 20090136534 | NOVEL RECOMBINANT BCG TUBERCULOSIS VACCINE DESIGNED TO ELICIT IMMUNE RESPONSES TO MYCOBACTERIUM TUBERCULOSIS IN ALL PHYSIOLOGICAL STAGES OF INFECTION AND DISEASE - A vaccine against | 05-28-2009 |
| 20090136535 | ADJUVANT ACTIVITIES OF MUTANTS OF LT-IIa AND LT-IIb ENTEROTOXIN LACKING BINDING TO GANGLIOSIDE - The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens. | 05-28-2009 |
| 20090148469 | Multicomponent meningococcal vaccine - A composition is provided comprising | 06-11-2009 |
| 20090148470 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - The present invention is primarily directed to a method for preventing infection of a mammalian subject with | 06-11-2009 |
| 20090155295 | VACCINE - A polypeptide derived from the periplasmic space of | 06-18-2009 |
| 20090155296 | MUTANTS OF LYSINE DECARBOXYLASE, VACCINES FOR PERIODONTITIS, AND METHODS OF USE - The present invention is directed to mutants of lysine decarboxylase, nucleic acids encoding the mutants, and vaccines comprising the mutants for inhibiting and reducing the development of periodontal diseases, including gingivitis and chronic periodontitis. The vaccine composition comprises a recombinant lysine decarboxylase mutant which is based on a native version of the enzyme from | 06-18-2009 |
| 20090162391 | VACCINE ANTIGENS FROM PISCIRICKETTSIA SALMONIS - The present invention discloses novel proteins, e.g., antigens, from | 06-25-2009 |
| 20090162392 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 06-25-2009 |
| 20090169577 | METHOD FOR STIMULATING IMMUNE RESPONSE AGAINST MORAXELLA CATARRHALIS - Provided is a method for stimulating in an individual an immune response against | 07-02-2009 |
| 20090175894 | METHODS AND MATERIALS FOR PRODUCING A GENERIC ANTI-AMYLOID IMMUNE RESPONSE IN MAMMALS - Compositions containing fibrillar aggregates of amyloidogenic polypeptides and adjuvants are described as well as methods of using such compositions to induce generic anti-amyloid immune responses in mammals. | 07-09-2009 |
| 20090186048 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the | 07-23-2009 |
| 20090202578 | SURFACE PROTEINS FROM COAGULASE-NEGATIVE STAPHYLOCOCCI AND STAPHYLOCOCCUS AUREUS THAT GENERATE CROSS-REACTIVE MONOCLONAL AND POLYCLONAL ANTIBODIES - Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive | 08-13-2009 |
| 20090208521 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEIN NMA0939 - The present invention is related to field of medicine, particularly to the development of pharmaceutical formulations containing NMA0939 protein. Formulations described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. NMA0939 protein was identified as a | 08-20-2009 |
| 20090214584 | Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis - The present invention is directed toward isolated | 08-27-2009 |
| 20090220538 | VACCINE FOR STAPHYLOCOCCAL INFECTIONS - The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology. | 09-03-2009 |
| 20090238842 | Vaccine for preventing and treating porcine progressive atrophic rhinitis - The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragments of recombinant subunit | 09-24-2009 |
| 20090246218 | S. AUREUS FIBRINOGEN BINDING PROTEIN GENE - The isolation of genes and proteins from | 10-01-2009 |
| 20090246219 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in | 10-01-2009 |
| 20090252756 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - Vaccine compositions and methods for protecting a mammalian subject against infection with | 10-08-2009 |
| 20090269368 | PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS - This invention provides | 10-29-2009 |
| 20090274717 | Genes and proteins, and their use - According to the present invention, a series of genes are identified in Group B | 11-05-2009 |
| 20090274718 | CHIMERIC PROTEINS THAT INDUCE EFFECTS DIRECTED AGAINST VIRUSES - The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from | 11-05-2009 |
| 20090274719 | CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION - The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of | 11-05-2009 |
| 20090280140 | Early detection of mycobacterial disease using peptides - A number of protein and glycoprotein antigens secreted by | 11-12-2009 |
| 20090280141 | Streptococcal Genes - Peptides derived from | 11-12-2009 |
| 20090285845 | Domains And Epitopes Of Meningococcal Protein NMB1870 - ‘NMB1870’ is a known surface protein in | 11-19-2009 |
| 20090285846 | MUTANTS OF CHOLESTEROL-DEPENDENT CYTOLYSINS AND USES THEREOF - Mutants of cholesterol-dependent cytolysins comprising at least one amino acid substitution in at least one of Loop 1, Loop 2, or Loop 3 of Domain 4, nucleic acids encoding such polypeptide mutants, and compositions and vaccines comprising such polypeptide mutants. | 11-19-2009 |
| 20090285847 | Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen | 11-19-2009 |
| 20090285848 | METHODS AND COMPOSITIONS FOR IMMUNIZING AGAINST PSEUDOMONAS INFECTION - Methods and compositions for inducing an immune response against | 11-19-2009 |
| 20090297548 | IMMUNOGENIC COMPOSITIONS COMPRISING ANTHRAX SPORE-ASSOCIATED PROTEINS - Compositions and methods for treating a | 12-03-2009 |
| 20090297549 | CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES - The invention relates to polynucleotides which are conserved or specific to one or more species of | 12-03-2009 |
| 20090304731 | RECOMBINANT ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SPOTTED FEVER RICKETTSIAE - The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group | 12-10-2009 |
| 20090317420 | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae - The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B | 12-24-2009 |
| 20090317421 | COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL BACTERIUM PROTEINS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 12-24-2009 |
| 20090324633 | Immunogens from Uropathogenic Escherichia Coli - Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic | 12-31-2009 |
| 20100008942 | Histophilus Somni Polynucleotides, Polypeptides and Methods of Use - This invention provides, among other things, protein, polypeptides, and fragments thereof, derived from bacteria | 01-14-2010 |
| 20100008943 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS - An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of | 01-14-2010 |
| 20100015170 | FLAGELLIN MUTANT VACCINE - The present invention provides a vaccine which effectively induces protective immune response particularly against flagellated pathogens (such as | 01-21-2010 |
| 20100015171 | VACCINES COMPRISING TB 10.4 - Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4 | 01-21-2010 |
| 20100021492 | MORAXELLA CATARRHALIS OUTER MEMBRANE PROTEIN-106 POLYPEPTIDE, GENE SEQUENCE AND USES THEREOF - The invention discloses the | 01-28-2010 |
| 20100034846 | NOVEL METHOD FOR TREATING H.PYLORI INFECTIONS - The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ. ID. No. 1, whereby such region is defined by
| 02-11-2010 |
| 20100047267 | Staphylococcus aureus proteins and nucleic acids - The invention provides proteins from | 02-25-2010 |
| 20100055123 | VACCINE AGAINST BURKHOLDERIA INFECTIONS - This invention relates to proteins expressed by ABC system genes of | 03-04-2010 |
| 20100055124 | BRACHYSPIRA PILOSICOLI 72kDa OUTER-MEMBRANE PROTEIN AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - The invention relates to | 03-04-2010 |
| 20100068219 | PEPTIDES THAT MIMIC NON-HUMAN CROSS-REACTIVE PROTECTIVE EPITOPES OF THE GROUP B MENINGOCOCCAL CAPSULAR POLYSACCHARIDE - Peptides that mimic the antigenic features of non human-cross-reactive protective epitopes of the MenB CP and nucleic acids encoding the peptide mimetics are disclosed. Antibodies elicited by these peptides do not bind to polysialic acid in host tissue and thus provide a safe and efficacious method for the treatment and/or prevention of Meningitis B. | 03-18-2010 |
| 20100068220 | BIOINFORMATIC METHOD FOR IDENTIFYING SURFACE-ANCHORED PROTEINS FROM GRAM-POSITIVE BACTERIA AND PROTEINS OBTAINED THEREBY - A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as | 03-18-2010 |
| 20100129391 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two | 05-27-2010 |
| 20100136039 | BORRELIA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from | 06-03-2010 |
| 20100136040 | USE OF THE 7F4 PROTEIN IN THE IN VITRO DIAGNOSIS OF MYCOPLASMA PNEUMONIAE INFECTIONS - A method for determining if an individual is infected by | 06-03-2010 |
| 20100136041 | COMBINATION GAS VACCINES AND THERAPEUTICS - Compositions useful for reducing the risk of, preventing, and/or treating | 06-03-2010 |
| 20100143394 | SYNTHETIC STREPTOCOCCUS PNEUMONIAE VACCINE - Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2 | 06-10-2010 |
| 20100158935 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 06-24-2010 |
| 20100166792 | Antigenic Polypeptides - The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides. | 07-01-2010 |
| 20100166793 | PROTEASE-RESISTANT MODIFIED SEB AND VACCINE CONTAINING THE SAME - A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof. | 07-01-2010 |
| 20100172926 | ANTHRAX COMPOSITIONS AND METHODS OF USE AND PRODUCTION - Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by | 07-08-2010 |
| 20100172927 | Vaccines Against Chlamydial Infection - Methods and compositions for the treatment or prevention of ocular | 07-08-2010 |
| 20100183653 | Fusion Proteins Comprising CD4 Minimal Modules and Methods of Use Thereof - Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 07-22-2010 |
| 20100183654 | IMMUNOREACTIVE PROTEIN ORTHOLOGS OF EHRLICHIA CANIS AND E. CHAFFEENSIS - The present invention concerns gp36 immunoreactive compositions for | 07-22-2010 |
| 20100183655 | Immunogenic Protein Constructs - Bacterial immunity proteins are utilized to increase immune response to an antigen of interest. | 07-22-2010 |
| 20100183656 | PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the | 07-22-2010 |
| 20100189737 | Meningococcal vaccines including hemoglobin receptor - The meningococcal haemoglobin receptor, HmbR, is used as a vaccine antigen in combination with one or more further antigens e.g. in combination with a meningococcal outer membrane vesicle, with another purified meningococcal antigen (e.g. fHBP, 287, NadA, NspA, NhhA, App, Omp85, LOS), with a conjugated meningococcal capsular saccharide, etc. | 07-29-2010 |
| 20100189738 | PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit | 07-29-2010 |
| 20100196409 | BASB006 POLYPEPTIDES FROM NEISSERIA MENINGITIDIS AND IMMUNOGENIC COMPOSITIONS THEREOF - The invention provides BASB006 polypeptides and polynucleotides encoding BASB006 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 08-05-2010 |
| 20100196410 | Streptococcus pneumoniae Antigens and Vaccines - The present invention relates to novel vaccines for the prevention or attenuation of infection by | 08-05-2010 |
| 20100203075 | CHLAMYDIA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a | 08-12-2010 |
| 20100215683 | PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS HYPERVIRULENT STRAINS - The invention provides protective antigens for Group B streptococcus hypervirulent strains. The fragments are useful in vaccine compositions to induce protection against | 08-26-2010 |
| 20100215684 | STREPTOCOCCUS M PROTEIN, IMMUNOGENIC FRAGMENTS, NUCLEIC ACIDS AND METHODS OF USE - Isolated M proteins, or M-like proteins, of | 08-26-2010 |
| 20100221277 | CHLAMYDIA PNEUMONIAE ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding hyperimmune serum-reactive antigens and fragments thereof, including hyperimmune serum-reactive antigens and fragments thereof derived from | 09-02-2010 |
| 20100221278 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 09-02-2010 |
| 20100221279 | KENNEL COUGH VACCINE - Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior to killing thereof. The protective protein(s) are operable to prevent or reduce the severity of a disease of the subject. The vaccine preparations of the invention do not require separation of the protective protein(s) from the host recombinant microorganism(s), thereby materially decreasing the complexity and cost of the vaccine formulations. A preferred vaccine against kennel cough includes recombinantly modified microorganisms which express protective antigens containing pertactin and filamentous hemagglutinin protein products. | 09-02-2010 |
| 20100247560 | MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF - Modified polypeptides based on the | 09-30-2010 |
| 20100247561 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length | 09-30-2010 |
| 20100255022 | VACCINE AGAINST CLOSTRIDIUM PERFRINGENS - There is provided a vaccine for controlling | 10-07-2010 |
| 20100260789 | PRODUCTS SPECIFIC TO PATHOGENIC STRAINS AND THEIR USE AS VACCINES AND IN IMMUNOTHERAPY - The invention relates to isolated antigenic polypeptides obtainable by a process comprising the steps of: 1—selecting on the basis of sequence analysis those of the polypeptides which are either located in the outermembrane or secreted by the bacteria, 2—identifying the genes coding for said polypeptides which are conserved in B2/D clinical isolates, 3—purifying the polypeptides identified in step 1, which are found in step 2 to be conserved in B2/D isolates, 4—testing the polypeptides for immunogenicity using animals models. Application for making vaccines compositions and immunotherapies. | 10-14-2010 |
| 20100260790 | S. Pneumoniae Antigens - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 10-14-2010 |
| 20100260791 | CHLAMYDIA ANTIGENS - antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as | 10-14-2010 |
| 20100272743 | Staphylococcus epidermidis nucleic acids and proteins - polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from | 10-28-2010 |
| 20100272744 | OMP85 Proteins of Neisseria Gonorrhoeae and Neisseria Meningitidis, Compositions Containing Same and Methods of Use Thereof - Nucleic acid and amino acid sequences of the Omp85 proteins of | 10-28-2010 |
| 20100285047 | THERAPEUTICS AND DIAGNOSTICS FOR GROUP A STREPTOCOCCI - Immunogenic compositions and vaccines are described comprising GAS Markers. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing GAS markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 11-11-2010 |
| 20100285048 | USE OF FLAGELLIN IN THE IMMUNOTHERAPY OF YERSINIA PESTIS - The invention provides a fusion protein comprising a flagellin adjuvant and a | 11-11-2010 |
| 20100291131 | CLOSTRIDIAL TOXIN NETB - The present invention relates to a polypeptide based toxin that originates from | 11-18-2010 |
| 20100291132 | Streptococcus uberis adhesion molecule - A polypeptide, designated as “ | 11-18-2010 |
| 20100297162 | S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of | 11-25-2010 |
| 20100310593 | Vaccines Against Chlamydia Infection - The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a | 12-09-2010 |
| 20100316662 | Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia - The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a | 12-16-2010 |
| 20100322955 | VIRULENCE GENES, PROTEINS, AND THEIR USE - A series of genes from | 12-23-2010 |
| 20100330113 | Vaccine Antigens - The present invention discloses novel proteins, e.g., antigens. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from | 12-30-2010 |
| 20110008378 | MODIFIED FLAGELLIN IMPROVED TOLL-LIKE RECEPTOR 5 STIMULATING ACTIVITY - Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin. | 01-13-2011 |
| 20110008379 | IMMUNOGENIC COMPOSITIONS CONTAINING ESCHERICHIA COLI H7 FLAGELLA AND METHODS OF USE THEREOF - Immunogenic compositions containing | 01-13-2011 |
| 20110008380 | Anaplasma Phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma - The invention provides methods and compositions for the detection and treatment of | 01-13-2011 |
| 20110014223 | MULTIMERIC PROTEINS ABLE TO INDUCE AN ANTIBODY RESPONSE AGAINST THE BETA-AMYLOID AND USE THEREOF - The present invention relates to the fields of molecular biology, immunology and medicine. Peptide sequences that belong to the beta amyloid peptide are exposed on the surface of a multimeric structure derived from the E2 component of alpha keto acid dehydrogenase. The molecules are useful for the production of vaccines for the treatment and/or prevention of Alzheimer's disease. | 01-20-2011 |
| 20110014224 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 01-20-2011 |
| 20110014225 | CROSS-REACTIVE DETERMINANTS AND METHODS FOR THEIR IDENTIFICATION - Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive | 01-20-2011 |
| 20110020382 | Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics - The invention provides isolated polypeptide and nucleic acid sequences derived from | 01-27-2011 |
| 20110020383 | NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF - Novel polynucleotide and amino acids of | 01-27-2011 |
| 20110020384 | THERAPEUTIC TB VACCINE - Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing | 01-27-2011 |
| 20110020385 | COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES - Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain. | 01-27-2011 |
| 20110020386 | VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE - is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in | 01-27-2011 |
| 20110027304 | YERSINIA PESTIS ANTIGENS, VACCINE COMPOSITIONS AND RELATED METHODS - The present invention provides antigens and vaccines useful in prevention of infection by | 02-03-2011 |
| 20110033491 | MULTICOMPONENT MENINGOCOCCAL VACCINE - A composition is provided comprising | 02-10-2011 |
| 20110033492 | VACCINES FOR BRUCELLOSIS - A polypeptide selected from the group consisting of BMEII0923, BMEI0411, a protective fragment of BMEII0923 and BMEI0411 and immunologically active variants of BMEII0923 and BMEIO411, which provides a protective immune response against | 02-10-2011 |
| 20110045011 | TRUNCATED RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN ANTIGEN (R56) OF ORIENTIA TSUTSUGAMUSHI STRAINS KARP, KATO and GILLIAM AND ITS USE IN ANTIBODY BASED DETECTION ASSAYS AND VACCINES - A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, | 02-24-2011 |
| 20110045012 | ANTI-ATHEROMA VACCINE - The invention relates to a recombinant protein comprising: a carrier portion; a first epitope capable of eliciting an anti-atheroma response; and a second epitope capable of eliciting an anti-atheroma response, characterised in that said first and second epitopes are distinct from one another. | 02-24-2011 |
| 20110052620 | HYBRID POLYPEPTIDES COMPRISING GBS-80 AND SPB1 PROTEINS OF STREPTOCOCCUS - GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH | 03-03-2011 |
| 20110059119 | IMMUNOGEN AGAINST CAMPYLOBACTER INFECTION - The invention relates to the use of | 03-10-2011 |
| 20110064761 | NOVEL SEQUENCES OF BRACHYSPIRA, IMMUNOGENIC COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF - Novel polynucleotide and amino acids of | 03-17-2011 |
| 20110070256 | Vaccine Antigens from Piscirickettsia Salmonis - The present invention discloses novel proteins, e.g., antigens, from | 03-24-2011 |
| 20110076299 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 03-31-2011 |
| 20110076300 | Hybrid Polypeptides Including Meningococcal fHBP Sequences - fHBP is a protein in | 03-31-2011 |
| 20110076301 | ANTIGENIC PROTEIN FRAGMENTS OF STREPTOCOCCUS PNEUMONIAE - Antigenic protein fragments of | 03-31-2011 |
| 20110097354 | SYSTEM FOR THE EXPRESSION OF PEPTIDES ON THE BACTERIAL SURFACE - Expression system of peptides on the bacterial surface characterised in that membrane-binding region the conserved sequence of the MSP1a protein of | 04-28-2011 |
| 20110104193 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 05-05-2011 |
| 20110104194 | IMMUNODOMINANT MYCOBACTERIUM TUBERCULOSIS PEPTIDES FROM CELL WALL PROTEINS FOR EARLY DIAGNOSIS AND IMMUNIZATION - A number of peptide epitopes and fragments from three | 05-05-2011 |
| 20110110966 | NOVEL IMMUNOGENIC PROTEINS OF LEPTOSPIRA - The invention provides novel immunogenic proteins LigA and LigB from | 05-12-2011 |
| 20110110967 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 05-12-2011 |
| 20110110968 | Human optimized Bacillus anthracis protective antigen - The invention relates to a humanized nucleic acid construct from | 05-12-2011 |
| 20110110969 | PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A | 05-12-2011 |
| 20110117119 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c protein sequence for use in the treatment or prevention of latent TB. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of latent tuberculosis. | 05-19-2011 |
| 20110142870 | Bacillus anthracis antigens, vaccine compositions, and related methods - The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by | 06-16-2011 |
| 20110142871 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS - Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 06-16-2011 |
| 20110150916 | COMPOSITIONS AND METHODS FOR TREATMENT OF GROUP A STREPTOCOCCI - Immunogenic compositions and vaccines are described comprising GAS Markers including AtmB Proteins. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers or antibodies against GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing GAS markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 06-23-2011 |
| 20110150917 | Small Cationic Antimicrobial Peptides - Cationic bacteriocin and lantibiotic peptides are provided and their immunomodulatory activities are described. Methods are provided for selectively enhancing innate immunity. Other methods are provided for selectively suppressing a proinflammatory response. Other methods are provided for identifying a compound or compounds which modulate an innate immune response. Pharmaceutical compositions comprising the cationic bacteriocin and lantibiotic peptides or polynucleotides are also provided. | 06-23-2011 |
| 20110150918 | TREATMENT OF MICROBIAL INFECTIONS - The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy. | 06-23-2011 |
| 20110159026 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO FLAGELLATED BACTERIUM - Vaccines comprising fliC and CD 154 polypeptides and | 06-30-2011 |
| 20110159027 | S. AGALACTIAE ANTIGENS I & II - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 06-30-2011 |
| 20110171245 | RECOMBINANT ANTIGEN FOR DIAGNOSIS AND PREVENTION OF MURINE TYPHUS - The invention relates to a recombinant immunogenic composition from | 07-14-2011 |
| 20110177111 | PROTECTIVE VACCINE AGAINST STAPHYLOCOCCUS AUREUS BIOFILMS COMPRISING CELL WALL-ASSOCIATED IMMUNOGENS - Vaccine formulations effective against | 07-21-2011 |
| 20110182923 | NOVEL GROUP B STREPTOCOCCUS ANTIGENS | 07-28-2011 |
| 20110182924 | PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the | 07-28-2011 |
| 20110189217 | METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE - This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided. | 08-04-2011 |
| 20110200631 | LAWSONIA INTRACELLULARIS VACCINES - The present invention relates to polynucleotide sequences encoding novel | 08-18-2011 |
| 20110206712 | TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 08-25-2011 |
| 20110206713 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the | 08-25-2011 |
| 20110212120 | Ykur polynucleotides and polypeptides - Nucleic acid encoding a novel bacterial polypeptide ykuR, the isolated ykuR polypeptide, its expression from host cells, and its use in screening for potential antibacterial agents. Inhibition of ykuR activity results in inhibition of bacterial growth. | 09-01-2011 |
| 20110212121 | RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections. | 09-01-2011 |
| 20110223186 | Clostridium toxin, and process for the preparation of immunogenic composition - The present invention relates to the field of bacterial toxic proteins, in particular toxins from | 09-15-2011 |
| 20110229507 | STABLE ANTHRAX VACCINE FORMULATIONS - Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection. | 09-22-2011 |
| 20110229508 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length | 09-22-2011 |
| 20110229509 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - Disclosed are polypeptides comprising an amino acid sequence structurally related to SEQ ID NO 1 and uses of such polypeptides and compositions thereof. SEQ ID NO 1 is a full length | 09-22-2011 |
| 20110236410 | KLEBSIELLA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a | 09-29-2011 |
| 20110243976 | COMPOSITIONS COMPRISING PNEUMOCOCCAL ANTIGENS - Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens. | 10-06-2011 |
| 20110243977 | SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES - β-hemolytic streptococci polynucleotides, polypeptides, particularly | 10-06-2011 |
| 20110243978 | ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 10-06-2011 |
| 20110250221 | Group A Streptococcus Pharmaceutical Compositions and Methods Thereof - Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A | 10-13-2011 |
| 20110250222 | ANTIGENIC POLYPEPTIDES OF CHLAMYDIA-RELATED BACTERIA FOR DIAGNOSIS AND VACCINE - The present invention relates to the disclosed transgenic peptides for use in the diagnosis of an infection by intracellular | 10-13-2011 |
| 20110250223 | HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 10-13-2011 |
| 20110256166 | Multivalent vaccines comprising recombinant viral vectors - The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease. | 10-20-2011 |
| 20110262475 | LYME DISEASE VACCINE - Antigenic polypeptides comprising linear immunodominant epitopes of | 10-27-2011 |
| 20110262476 | MUTANT BACTERIAL GLYCOPROTEINS AND USES THEREOF - The present invention relates to the use of mutant glycoproteins from pathogenic bacteria lacking one or more phosphorylcholine and/or glycosylation post-translational modifications as immunogens. These post-translational modifications act as masking structures that elicit an immune response which does not confer protection on an infected individual. The removal or modification of these masking structures alters the protein such that it elicits a stronger immune response to the protein and/or the bacterial pathogen. Particular examples are pilin proteins and nitrite reductase glycoproteins of | 10-27-2011 |
| 20110262477 | Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 10-27-2011 |
| 20110268757 | USE OF PHENOL-SOLUBLE MODULINS FOR VACCINE DEVELOPMENT - The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer | 11-03-2011 |
| 20110268758 | TUBERCULOSIS ANTIGEN DETECTION ASSAYS AND VACCINES - The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules, nucleic acid molecules, vaccine compositions, diagnostic assays, and methods of diagnosis and monitoring treatment related to these TB antigens. | 11-03-2011 |
| 20110280900 | CLOSTRIDIUM CHAUVOEI POLYPEPTIDE, DNA ENCODING THE POLYPEPTIDE AND A VACCINE COMPRISING THE POLYPEPTIDE - The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of | 11-17-2011 |
| 20110287046 | MODIFIED STREPTOCOCCUS PNEUMONIA PNEUMOLYSIN (PLY) POLYPEPTIDES - This disclosure relates to modified | 11-24-2011 |
| 20110293652 | CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 12-01-2011 |
| 20110300171 | FACTOR H BINDING PROTEIN IMMUNOGENS - The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins. | 12-08-2011 |
| 20110305721 | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 12-15-2011 |
| 20110311570 | PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the | 12-22-2011 |
| 20110318378 | Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use - Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of | 12-29-2011 |
| 20120003256 | TUBERCULOSIS ANTIGENS, IMMUNOGENIC COMPOSITIONS, DIAGNOSTICS AND METHODS RELATED TO THE SAME - Provided herein are Mtb polynucleotides, recombinant Mtb peptides and polypeptides, immunogenic Mtb antigens, and Mtb antibodies. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides kits comprising Mtb polynucleotides, Mtb polypeptides, Mtb antibodies, and combinations thereof. | 01-05-2012 |
| 20120003257 | RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing | 01-05-2012 |
| 20120003258 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 01-05-2012 |
| 20120014982 | Methods and Compositions for Immunizing Against Chlamydia Infection - The present invention relates, in part, to methods and compositions for immunizing against infection by | 01-19-2012 |
| 20120014983 | RECOMBINANT ALPHA-HEMOLYSIN POLYPEPTIDE OF STAPHYLOCOCCUS AUREUS, HAVING A DELETION IN THE STEM DOMAIN AND HETEROLOGOUS SEQUENCES INSERTED - It refers to a recombinant alpha-hemolysin polypeptide of | 01-19-2012 |
| 20120027793 | COMPOSITIONS COMPRISING CHLAMYDIA ANTIGENS - There is provided a composition for inducing an immune response to a | 02-02-2012 |
| 20120034257 | METHYLATED HEPARIN-BINDING HEMAGGLUTININ RECOMBINANT MYCOBACTERIAL ANTIGEN, PREPARATION METHOD AND IMMUNOGENIC COMPOSITIONS COMPRISING SAME - The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for preparing such a sequence, the sequence being previously produced in a non-methylated recombinant form then methylated by post-translational modification. The invention further concerns recombinant tools, vectors and host cells for implementing post-translational enzymatic methylation of the recombinant HBHA. The invention finally concerns immunogenic compositions comprising methylated, native or recombinant HBHA, such compositions being useful for preparing vaccines against mycobacterial infections. | 02-09-2012 |
| 20120034258 | POLYPEPTIDES AND IMMUNIZING COMPOUNDS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 02-09-2012 |
| 20120039924 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE - Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD. | 02-16-2012 |
| 20120039925 | TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION - The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms ( | 02-16-2012 |
| 20120064103 | COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEIN AND PNEUMOCOCCAL SACCHARIDE CONJUGATES - An immunogenic composition comprising: (i) a conjugated pneumococcal capsular saccharide; and (ii) a meningococcal factor H binding protein (fHBP) antigen, and not including meningococcal outer membrane vesicles, is useful for immunising a subject against bacterial meningitis. | 03-15-2012 |
| 20120064104 | COMBINATIONS INCLUDING PNEUMOCOCCAL SEROTYPE 14 SACCHARIDE - Meningococcal lipooligosaccharide and pneumococcal serotype 14 capsular saccharide share an antigen that can cross-react with human tissue. The invention provides various ways of minimising the production of autoreactive antibodies when these two antigens are co-administered. | 03-15-2012 |
| 20120064105 | Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered | 03-15-2012 |
| 20120070457 | Polypeptides from neisseria meningitidis - Polypeptides comprising | 03-22-2012 |
| 20120070458 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 03-22-2012 |
| 20120076813 | USES OF GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS - The present invention relates to polypeptide fragments, including variants and analogs, of | 03-29-2012 |
| 20120076814 | COMBINATIONS OF PNEUMOCOCCAL RRGB CLADES - Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain. | 03-29-2012 |
| 20120087939 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SHIGA TOXIN-PRODUCING ESCHERICHIA COLI INFECTION - Compositions and methods for stimulating an immune response against Shiga toxin-producing | 04-12-2012 |
| 20120093850 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective | 04-19-2012 |
| 20120093851 | CHLAMYDIA ANTIGENS - The invention provides | 04-19-2012 |
| 20120093852 | NON-LIPIDATED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS - The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B | 04-19-2012 |
| 20120100171 | HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS - This invention relates to immunogenic compositions for inducing an immune response against an antigen of interest. In particular, the invention provides immunogenic compositions comprising an antigen-carrier conjugate, wherein the carrier is a bacterial toxin that contains a signal peptide. The invention also provides methods of generating immunogenic compositions with enhanced immunogenicity, comprising adding a signal peptide to the bacterial carrier in an antigen-carrier conjugate, such as a hapten-carrier conjugate. The invention also provides methods for inducing an immune response to a hapten in a subject using these immunogenic compositions. | 04-26-2012 |
| 20120100172 | IMMUNOGENIC STREPTOCOCCUS PNEUMONIAE PEPTIDES AND PEPTIDE-MULTIMERS - The present invention relates to immunogenic peptides, including variants and analogs derived from | 04-26-2012 |
| 20120107339 | Chimeric Factor H Binding Proteins (fHBP) Containing a Heterologous B Domain and Methods of Use - Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of | 05-03-2012 |
| 20120107340 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 05-03-2012 |
| 20120107341 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 05-03-2012 |
| 20120114684 | COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a | 05-10-2012 |
| 20120114685 | COMPOSITIONS COMPRISING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF - The present invention provides recombinant | 05-10-2012 |
| 20120114686 | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS - Disclosed are methods and compositions for treating or preventing a | 05-10-2012 |
| 20120114687 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( | 05-10-2012 |
| 20120121637 | CHIMERIC FACTOR H BINDING PROTEINS (FHBP) AND METHODS OF USE - Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of | 05-17-2012 |
| 20120121638 | Polypeptide Derived From Enterococcus And Its Use For Vaccination - A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an | 05-17-2012 |
| 20120121639 | PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the | 05-17-2012 |
| 20120128707 | STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS - The invention provides proteins and nucleic acid sequences from | 05-24-2012 |
| 20120128708 | DIAGNOSTIC MYCOBACTERIUM TUBERCULOSIS TEST - A method of diagnosing | 05-24-2012 |
| 20120128709 | EXPRESSION OF RECOMBINANT PROTEINS - The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can be used to produce commercial quantities of proteins such as antigens, which can be used to prepare pharmaceutical compositions. | 05-24-2012 |
| 20120135024 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 05-31-2012 |
| 20120135025 | CHLAMYDIA ANTIGENS AND USES THEREOF - The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses). The present invention provides methods of prophylaxis and/or treatment of chlamydia-mediated diseases comprising administering an immunogenic composition including one or more of the novel antigens described herein. | 05-31-2012 |
| 20120135026 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 05-31-2012 |
| 20120135027 | PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS - Chimera proteins including: (i) at least one sequence of a DbpA protein of a | 05-31-2012 |
| 20120141521 | Immunogenic Compositions for Streptococcus agalactiae - The invention relates to immunogenic polypeptides derived from epitopes in a | 06-07-2012 |
| 20120141522 | RECOMBINANT PROTECTIVE PROTEIN FROM STREPTOCOCCUS PNEUMONIAE - The present invention discloses amino acid sequences and nucleic acid sequences relating to a | 06-07-2012 |
| 20120141523 | IMMUNOGENIC COMPOSITION COMPRISING ANTIGENIC S. AUREUS PROTEINS - The present application relates to an immunogenic composition comprising a fragment of a staphylococcal Isd protein such as IsdA, IsdB, IsdC or IsdH which comprises a NEAT domain. Fusion proteins comprising a NEAT domain of a first staphylococcal Isd protein and a NEAT domain from a second Isd protein are also disclosed as well as fusion proteins comprising a NEAT domain of a staphylococcal Isd protein involved in an iron/heme uptake system and a ligand binding domain of a staphylococcal extracellular component binding protein, for example ClfA, ClfB, SdrC, SdrD or SdrE. | 06-07-2012 |
| 20120148614 | Interaction of Moraxella Catarrhalis with Epithelial Cells, Extracellular Matrix Proteins and the Complement System - The present disclosure relates to surface proteins of | 06-14-2012 |
| 20120148615 | POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE - Polypeptides comprising non-typeable | 06-14-2012 |
| 20120148616 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 06-14-2012 |
| 20120148617 | MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NBM1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870. | 06-14-2012 |
| 20120148618 | MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870. | 06-14-2012 |
| 20120148619 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 06-14-2012 |
| 20120156236 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 06-21-2012 |
| 20120164166 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 06-28-2012 |
| 20120171236 | IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE - The published genomic sequence of | 07-05-2012 |
| 20120171237 | RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections. | 07-05-2012 |
| 20120171238 | S. AUREUS ALLERGEN - The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with | 07-05-2012 |
| 20120177678 | COMPOSITIONS AND METHODS FOR TREATMENT OF CERVICAL DYSPLASIA - The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant | 07-12-2012 |
| 20120177679 | MATRIX METALLOPROTEINASE 11 VACCINE - Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy. | 07-12-2012 |
| 20120177680 | POLYPEPTIDES AND METHODS FOR THE SPECIFIC DETECTION OF ANTIBODIES IN PATIENTS WITH A BORRELIA INFECTION - The present disclosure relates to proteins derived from OspC from bacteria of the genus | 07-12-2012 |
| 20120183570 | ANTIGEN COMPOSITIONS AND METHODS OF INHIBITING CAMPYLOBACTER JEJUNI BACTERIAL INFECTION AND USES OF THE ANTIGEN COMPOSITIONS - Methods and compositions for reducing the incidence of | 07-19-2012 |
| 20120189649 | Vaccines and Compositions Against Streptococcus Pneumoniae - is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in | 07-26-2012 |
| 20120189650 | IMMUNOGENIC COMPOSITION COMPRISING VARIANTS OF STAPHYLOCOCCAL CLUMPING FACTOR A - The present invention relates to ClfA polypeptides wherein amino acid Y474 or an amino acid adjacent to Y474 is mutated such that fibrinogen binding activity is decreased compared to an equivalent ClfA polypeptide without mutation of Y474 or an amino acid adjacent to Y474 as well as immunogenic compositions, vaccines, processes and uses of such mutated ClfA polypeptides. | 07-26-2012 |
| 20120195919 | HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 08-02-2012 |
| 20120195920 | STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE - The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection. | 08-02-2012 |
| 20120201844 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 08-09-2012 |
| 20120207776 | CONSERVED ESCHERICHIA COLI IMMUNOGENS - Homologs of the | 08-16-2012 |
| 20120207777 | DETOXIFIED ESCHERICHIA COLI IMMUNOGENS - Detoxified variants of the pathogenic | 08-16-2012 |
| 20120207778 | NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B - The invention provides proteins from group B | 08-16-2012 |
| 20120207779 | Anaplasma phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma - The invention provides methods and compositions for the detection and treatment of | 08-16-2012 |
| 20120219578 | NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria | 08-30-2012 |
| 20120225091 | MODIFIED LIVE (JMSO STRAIN) HAEMOPHILUS PARASUIS VACCINE - The present invention is a live vaccine from a culture of cells of | 09-06-2012 |
| 20120237536 | COMBINATION VACCINES AGAINST RESPIRATORY TRACT DISEASES - Influenza, pneumococcus and/or RSV vaccines are administered as a combination vaccine while retaining immunogenic efficacy. This combination simplifies immunisation against these two lower respiratory tract infections. The pneumococcal vaccine ideally includes at least one pneumococcal polypeptide. | 09-20-2012 |
| 20120237537 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 09-20-2012 |
| 20120251565 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING BURKHOLDERIA INFECTION - The present invention provides a protein or a fragment or a variant of said protein, wherein the protein, fragment, or variant is capable of producing a protective immune response in an animal, wherein the immune response is protective against infection by | 10-04-2012 |
| 20120258128 | Infection Factor Assay - There is provided a method of selecting an anti-macrophage micro-organism comprising an anti-macrophage factor, the method comprising the steps of:
| 10-11-2012 |
| 20120263745 | ANTICHLAMYDIAL AGENTS - An antichlamydial agent comprising an inhibitor of Chlamydial Protease-like Activity Factor (CPAF). The inhibitor of CPAF can comprise a CPAF inhibitory segment and can optionally include one or more additional residues or domains. Also provided are compositions comprising an inhibitor of CPAF, methods of identifying an inhibitor of CPAF, and methods of treating a | 10-18-2012 |
| 20120269841 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 10-25-2012 |
| 20120269842 | ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES - The disclosure relates to fusions of enterotoxigenic | 10-25-2012 |
| 20120269843 | S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of | 10-25-2012 |
| 20120276129 | NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria | 11-01-2012 |
| 20120276130 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR RHEUMATIC HEART DISEASE BASED UPON GROUP A STREPTOCOCCUS MARKERS - This invention is in the field of identifying patients having rheumatic heart disease (RHD) associated with | 11-01-2012 |
| 20120282288 | Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides - Recombinant carrier molecules having amino acid sequences from thermostable enzymes and methods of use for expression, recovery and delivery of foreign sequences (peptides and polypeptides) produced in different systems (bacteria, yeast, DNA, cell cultures such as mammalian, plant, insect cell cultures, protoplast and whole plants in vitro or in vivo are provided. The recombinant carrier molecule using sequences from lichenase B (Lic B) were also made and used as part of carrier protein to express, recover and deliver a variety of target polypeptides of interest. | 11-08-2012 |
| 20120282289 | STAPHYLOCOCCAL ANTIGENS - The present invention provides novel sequences encoding | 11-08-2012 |
| 20120282290 | Mycobacterial Vaccines - There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections. | 11-08-2012 |
| 20120288517 | Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof - Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of | 11-15-2012 |
| 20120294880 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 11-22-2012 |
| 20120294881 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide of | 11-22-2012 |
| 20120294882 | MODIFIED TUBERCULOSIS ANTIGENS - Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis. | 11-22-2012 |
| 20120301495 | ANTIGEN PEPTIDE AND USE THEREOF - In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes. | 11-29-2012 |
| 20120301496 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 11-29-2012 |
| 20120308595 | Novel Immunogenic Compositions For The Prevention And Treatment of Meningococcal Disease - The present invention relates to | 12-06-2012 |
| 20120308596 | NOVEL STREPTOCOCCUS ANTIGENS - proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of | 12-06-2012 |
| 20120308597 | SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION - Regions of | 12-06-2012 |
| 20120315292 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 12-13-2012 |
| 20120321656 | OLIGOPEPTIDES AND THEIR USE FOR TREATING INFECTIOUS DISEASES - The invention discloses identification, method of making and therapeutic use of synthetic oligopeptides for the treatment of infectious diseases, in particular tuberculosis. The oligopeptides are designed using virulence mediating protein for | 12-20-2012 |
| 20120321657 | GROUP A STREPTOCOCCUS MULTIVALENT VACCINE - Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A | 12-20-2012 |
| 20120328642 | BOTULINUM NEUROTOXIN ANTIGENIC COMPOSITIONS AND METHODS - Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided. | 12-27-2012 |
| 20120328643 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 12-27-2012 |
| 20120328644 | Low Antigen-dose Immunization for Maximizing T-helper Cell 1 (Th1) Immunity Against a Pathogen - Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response. | 12-27-2012 |
| 20130004530 | VACCINE COMPOSITION - Neisserial immunogenic compositions and vaccines, their manufacture and methods for the use of such compositions in medicine are provided herein. | 01-03-2013 |
| 20130004531 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI - Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic | 01-03-2013 |
| 20130011428 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF - The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of | 01-10-2013 |
| 20130017214 | BACTEREMIA-ASSOCIATED ANTIGEN FROM STAPHYLOCOCCUS AUREUSAANM Edgeworth; JonathanAACI LondonAACO GBAAGP Edgeworth; Jonathan London GB - The BAA antigen of | 01-17-2013 |
| 20130017215 | SECRETED CAMPYLOBACTER FLAGELLA COREGULATED PROTEINS AS IMMUNOGENS - The invention relates to an immunogenic composition composed of secreted polypeptides derived from | 01-17-2013 |
| 20130022633 | MENINGOCOCCAL fHBP POLYPEPTIDES - The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH. | 01-24-2013 |
| 20130022634 | NEW COMPOSITION AND METHODS FOR TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES - The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically, the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1-subunit of the cholera toxin (CTA1), a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit, the amino acids corresponding to the amino acid 7, arginine, and amino acid 187, cysteine, in the native CTA1 have been replaced. | 01-24-2013 |
| 20130028926 | BIOSYNTHETIC SYSTEM THAT PRODUCES IMMUNOGENIC POLYSACCHARIDES IN PROKARYOTIC CELLS - The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins. | 01-31-2013 |
| 20130028927 | METHOD OF DIAGNOSING AND TREATING MELIOIDOSIS - Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis. These methods include inducing an immune response to melioidosis and/or using an inhibitory nucleic acid, such as a siRNA or antisense molecule, to decrease a melioidosis associated molecule expression in order to treat melioidosis. | 01-31-2013 |
| 20130034577 | Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia - The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a | 02-07-2013 |
| 20130058967 | RECOMBINANT MODIFIED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN FOR USE IN VACCINES - The invention relates to improved methods of producing and recovering sporulation-deficient | 03-07-2013 |
| 20130064845 | BACTERIAL VACCINE COMPONENTS FROM STAPHYLOCOCCUS AUREUS AND USES THEREOF - Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the | 03-14-2013 |
| 20130064846 | NEISSERIAL ANTIGENS - The invention provides proteins from | 03-14-2013 |
| 20130071423 | COMBINATION VACCINE FOR STREPTOCOCCUS - The invention relates to the use of a combination of SP | 03-21-2013 |
| 20130078271 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection. | 03-28-2013 |
| 20130084304 | VACCINE AND METHODS TO REDUCE CAMPYLOBACTER INFECTION - Vaccine vectors and methods for enhancing resistance to | 04-04-2013 |
| 20130095132 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( | 04-18-2013 |
| 20130101613 | PROTECTIVE PROTEINS OF S. AGALACTIAE, COMBINATIONS THEREOF AND METHODS OF USING THE SAME - The invention relates to a composition comprising at least two protective proteins against | 04-25-2013 |
| 20130101614 | NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS - Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases. | 04-25-2013 |
| 20130101615 | METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS - This invention is a method for immunizing, preventing or treating a | 04-25-2013 |
| 20130108659 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINE | 05-02-2013 |
| 20130115237 | THERAPEUTIC IMMUNIZATION IN HIV INFECTED SUBJECTS TO AUGMENT ANTIRETROVIRAL TREATMENT - The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a | 05-09-2013 |
| 20130115238 | MENINGOCOCCAL FHBP POLYPEPTIDES - fHBP is a protein in | 05-09-2013 |
| 20130122034 | STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED THEREON - The novel protein SA1789 from | 05-16-2013 |
| 20130129763 | INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM - The present disclosure relates to surface proteins of | 05-23-2013 |
| 20130129764 | COMPOSITIONS AND METHODS TO DETECT VARIOUS INFECTIOUS ORGANISMS - The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm ( | 05-23-2013 |
| 20130129765 | Compositions and Methods for Stimulating Immune Response Against Moraxella Catarrhalis - This invention provides a method for stimulating in an individual an immune response against | 05-23-2013 |
| 20130136760 | STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS - The present invention relates to antigens, more particularly antigenS of | 05-30-2013 |
| 20130136761 | S. PNEUMONIAE ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 05-30-2013 |
| 20130136762 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 05-30-2013 |
| 20130149324 | THERAPEUTIC TB VACCINE - Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis. | 06-13-2013 |
| 20130149325 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES AND NUCLEOTIDES - The present invention relates to isolated | 06-13-2013 |
| 20130149326 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 06-13-2013 |
| 20130149327 | YERSINIA PESTIS ANTIGENS, VACCINE COMPOSITIONS, AND RELATED METHODS - The present invention provides antigens and vaccines useful in prevention of infection by | 06-13-2013 |
| 20130156802 | Cholera Toxin Chimera and its Use as a Staph Vaccine - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of | 06-20-2013 |
| 20130156803 | COMPOSITIONS AND METHODS RELATED TO P6 - Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM. | 06-20-2013 |
| 20130156804 | Porin B (PorB) as a Therapeutic Target for Prevention and Treatment of Infection by Chlamydia - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit | 06-20-2013 |
| 20130156805 | CHIMERIC MOMP ANTIGEN - The present invention regards polypeptides capable of eliciting an immunological response that is protective against | 06-20-2013 |
| 20130164317 | ANTIMICROBIAL AGENT, BACTERIAL STRAIN, BIOSYNTHESIS, AND METHODS OF USE - Provided herein is a biologically pure culture of | 06-27-2013 |
| 20130171183 | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 07-04-2013 |
| 20130171184 | VACCINE AGAINST N. MENINGITIDIS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention comprise the Hsf (also called Msf) and Opc neisserial antigens. These antigens have been found to be the two mechanisms by which | 07-04-2013 |
| 20130183330 | RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing | 07-18-2013 |
| 20130183331 | IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON - outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the | 07-18-2013 |
| 20130189295 | COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS - The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. | 07-25-2013 |
| 20130195907 | OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of | 08-01-2013 |
| 20130209500 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two | 08-15-2013 |
| 20130209501 | Immunogenic Compositions of Staphylococcus Epidermidis Polypeptide Antigens - The present invention relates to immunogenic compositions, comprising polypeptides isolated from | 08-15-2013 |
| 20130216568 | IMMUNOGENIC PROTEINS AND COMPOSITIONS - The invention provides proteins and compositions for the treatment and prevention of | 08-22-2013 |
| 20130230550 | METHODS AND COMPOSITIONS INVOLVING PROTECTIVE STAPHYLOCOCCAL ANTIGENS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 09-05-2013 |
| 20130236488 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES USEFUL IN THE PREVENTION OF PERIODONTAL DISEASE - The invention is directed to vaccine compositions and methods based on | 09-12-2013 |
| 20130236489 | DEVELOPMENTS IN MENINGOCOCCAL OUTER MEMBRANE VESICLES - A first aspect of the invention provides meningococcal outer membrane vesicles in which NHBA is over-expressed. A second aspect of the invention provides meningococcal outer membrane vesicles in which NadA is over-expressed. A third aspect of the invention provides a panel of bacterial strains, each member of which is isogenic except for a single gene which in each strain encodes a different variant of an antigen of interest. | 09-12-2013 |
| 20130243806 | POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 09-19-2013 |
| 20130243807 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF - In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from | 09-19-2013 |
| 20130251738 | VACCINES - There is provided a method of identifying a protective | 09-26-2013 |
| 20130251739 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS DIAGNOSTIC REAGENTS AND VACCINES - The present invention is directed to reagents useful for generating immune responses to | 09-26-2013 |
| 20130259888 | MEANS OF CONTROLLING INFECTION PERSISTENCE OF HELICOBACTER PYLORI - The present invention relates to a means of controlling infection persistence of | 10-03-2013 |
| 20130259889 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 10-03-2013 |
| 20130266604 | PEPTIDE CONTAINING MULTIPLE N-LINKED GLYCOSYLATION SEQUONS - Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in | 10-10-2013 |
| 20130266605 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR - The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signaling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-Cd40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules. | 10-10-2013 |
| 20130266606 | POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian | 10-10-2013 |
| 20130266607 | Cholera Toxin Chimera and its Use as a Staph Vaccine - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of | 10-10-2013 |
| 20130273091 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof. | 10-17-2013 |
| 20130273092 | USES OF YERSINIA YOPE PEPTIDE, GENE AND SUBPARTS THEREOF AS A PLAGUE VACCINE COMPONENT AND ASSAYS FOR YERSINIA PESTIS-SPECIFIC T CELLS - This invention relates to vaccine formulations comprising the | 10-17-2013 |
| 20130273093 | Method for Immunising a Subject against Mycobacterium Tuberculosis or Mycobacterium Bovis - The invention relates to a method for immunising a subject against | 10-17-2013 |
| 20130280286 | MEDICAMENT FOR LCT POISONING - The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular | 10-24-2013 |
| 20130280287 | RECOMBINANT MYCOBACTERIUM AS VACCINE FOR USE IN HUMANS - The invention relates to a recombinant vaccine providing protective immunity especially against tuberculosis in human subjects. | 10-24-2013 |
| 20130280288 | PEPTIDES PROTECTIVE AGAINST S. PNEUMONIAE AND COMPOSITIONS, METHODS AND USES RELATING THERETO - The present invention relates to a protective peptide of | 10-24-2013 |
| 20130280289 | MYCOBACTERIUM ANTIGENIC COMPOSITION - Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided. | 10-24-2013 |
| 20130287808 | VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS - The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2AP) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type IV pilus-associated proteins and the β2AP. | 10-31-2013 |
| 20130287809 | MYCOBACTERIUM ANTIGENIC COMPOSITION - Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided. | 10-31-2013 |
| 20130295127 | VACCINE AGAINST CLOSTRIDIUM PERFRINGENS - There is provided a vaccine for controlling | 11-07-2013 |
| 20130309264 | NOVEL ANTIGEN OF ENTEROCOCCAL PATHOGENS AND USE THEROF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS - The present invention relates to antigens, more particularly protein antigens of enterococcal pathogens which are useful as vaccine components for therapy and/or prophylaxis. | 11-21-2013 |
| 20130315946 | VACCINE COMPOSITION AGAINST STREPTOCOCCUS PYOGENES INFECTION - The present invention relates to a vaccine composition against | 11-28-2013 |
| 20130323274 | ESCHERICHIA COLI IMMUNOGENS WITH IMPROVED SOLUBILITY - Variants of the pathogenic | 12-05-2013 |
| 20130330369 | Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof - The present invention provides a method of tolerizing a subject to | 12-12-2013 |
| 20130330370 | NOVEL SEQUENCES OF BRACHYSPIRA, IMMUNOGENIC COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF - Novel polynucleotide and amino acids of | 12-12-2013 |
| 20130330371 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 12-12-2013 |
| 20130337003 | Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered | 12-19-2013 |
| 20140004138 | DETOXIFIED PNEUMOCOCCAL NEURAMINIDASE AND USES THEREOF | 01-02-2014 |
| 20140004139 | SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION | 01-02-2014 |
| 20140004140 | GROUP B STREPTOCOCCUS VACCINE | 01-02-2014 |
| 20140010835 | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO - The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a | 01-09-2014 |
| 20140010836 | ANTIGENIC GLY1 POLYPEPTIDES - We disclose antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against bacterial animal pathogens in particular bacterial pathogens of agriculturally important animal species and companion animals and including zoonotic Gram negative bacterial species. | 01-09-2014 |
| 20140017270 | SMALL STREPTOCOCCUS PYOGENES ANTIGENS AND THEIR USE - The present invention relates to a peptide consisting of one antigen of | 01-16-2014 |
| 20140017271 | IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from | 01-16-2014 |
| 20140023674 | METHODS AND COMPOSITIONS EMPLOYING IMMUNOGENIC FUSION PROTEINS - Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. | 01-23-2014 |
| 20140030284 | COMPOSITIONS COMPRISING CHIMERIC OSPA MOLECULES AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 01-30-2014 |
| 20140030285 | Altered OSPA of Borrelia Burgdorferi - Provided herein are OspA polypeptides from Lyme Disease-causing | 01-30-2014 |
| 20140030286 | PEPTIDES CAPABLE OF FORMING A CONVALENT COMPLEX, AND USES THEREOF - The present invention relates to a peptide capable of forming a covalent complex consisting either of the Jo peptide, a derivative or a fragment thereof, or of the In peptide, a derivative or a fragment thereof. The present invention relates to the various uses thereof. | 01-30-2014 |
| 20140030287 | ENOLASE PEPTIDE CONJUGATE VACCINES AGAINST STAPHYLOCOCCUS AUREUS - The present invention relates to peptides of the enolase protein from | 01-30-2014 |
| 20140037668 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 02-06-2014 |
| 20140037669 | MULTICOMPONENT IMMUNOGENIC COMPOSITION FOR THE PREVENTION OF BETA-HEMOLYTIC STREPTOCOCCAL (BHS) DISEASE - A number of β-hemolytic streptococci polynucleotides and polypeptides, particularly | 02-06-2014 |
| 20140037670 | CYAA-CARRIED POLYPEPTIDE(S) AND USE TO INDUCE BOTH THERAPEUTIC AND PROPHYLACTIC IMMUNE RESPONSES - The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s). | 02-06-2014 |
| 20140037671 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 02-06-2014 |
| 20140044747 | COMBINATION VACCINE - The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides. | 02-13-2014 |
| 20140050756 | NOVEL OPRF/I FUSION PROTEINS, THEIR PREPARATION AND USE - The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the | 02-20-2014 |
| 20140050757 | Compositions and Methods for Detection of Antibodies Specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl) - The invention provides methods and compositions for the detection and treatment of | 02-20-2014 |
| 20140050758 | FERMENTATION PROCESS - The present invention provides a process for periplasmic expression of a bacterial toxoid comprising the steps of: | 02-20-2014 |
| 20140072592 | METHOD OF PREPARING ANTIGEN FOR ACQUIRING ANTI-HYDROPHOBIC PEPTIDE ANTIBODY - The object of the present invention is to provide a method to obtain an antibody for a hydrophobic peptide, which can be used for general purposes easily and with great reliability. Also provided is a method for preparing an antigen characterized in that a hydrophobic peptide, which is unbound to carrier protein, is used as high-molecular-weight aggregates in an aqueous solution containing a nonionic surfactant. | 03-13-2014 |
| 20140079727 | NEW ENDOLYSIN PLYP40 - The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO:1. The present invention further relates to the nucleic acid molecules comprising a nucleotide sequence coding for the polypeptide, vectors comprising the nucleic acid molecules, and host cells for the expression of the polypeptides. In addition, the present invention relates to the use of the polypeptide as a human medical, veterinary medical or diagnostic substance, as an antimicrobial substance in food, in cosmetics, as disinfecting agent or in the environmental field. | 03-20-2014 |
| 20140086948 | TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 03-27-2014 |
| 20140086949 | Ghrelin Mimetic Polypeptide Hapten Immunoconjugates Having Improved Solubility and Immunogenicity and Methods of Use Thereof - Immunoconjugates for impeding weight gain and treating obesity in a subject are disclosed. The immunoconjugates comprise a ghrelin mimetic polypeptide hapten, a spacer moiety comprising one of more polyethylene glycol (PEG) units, and a protein carrier moiety. Immunoconjugates optionally include a conjugation moiety for conjugating the polypeptide hapten with a linker moiety or the protein carrier moiety and a linker moiety for conjugating the conjugation moiety with the protein carrier moiety. | 03-27-2014 |
| 20140086950 | RECOMBINANT LACTOCOCCUS LACTIS EXPRESSING ESCHERICHIA COLI COLONIZATION FACTOR ANTIGEN I (CFA/I) FIMBRIAE AND THEIR METHODS OF USE - The present disclosure relates generally to therapeutic compositions comprising recombinant bacteria. Further, the disclosure elaborates upon methods of utilizing the taught therapeutic compositions to treat autoimmune and inflammatory disease. The present teachings also relate to the disclosed recombinant bacteria and methods of producing the recombinant bacteria utilized in the compositions and methods. Further taught herein are dietary supplements and food additive compositions comprising the taught recombinant bacteria. | 03-27-2014 |
| 20140093529 | IMMUNOGENIC COMPOSITION - The present invention relates to fusion proteins comprising fragments of toxin A and toxin B from | 04-03-2014 |
| 20140105926 | IMMUNOGENIC COMPOSITION - The present invention relates to immunogenic compositions comprising one or more | 04-17-2014 |
| 20140105927 | IMMUNOGENIC COMPOSITION - The present invention relates to an immunogenic composition comprising
| 04-17-2014 |
| 20140112948 | Multi-Target Recombination Gene and the Application of its Protein to Prevent and Cure Helicobacter Pylori - The present invention discloses a multi-target recombination gene and the application of its protein to prevent and cure | 04-24-2014 |
| 20140112949 | Recombinant Mycobacterium Avium Subsp. Paratuberculosis Proteins Induce Immunity and Protect Against Infection - Compositions of immunogenic proteins of | 04-24-2014 |
| 20140120128 | USE OF YSCF, TRUNCATED YSCF AND YSCF HOMOLOGS AS ADJUVANTS - An antigenic composition comprising an antigen and an effective adjuvant, the adjuvant comprising isolated or recombinant YscF, a YscF fragment, truncated YscF (trYscF), or homologs thereof. A method of inducing an enhanced immune response comprising administering an antigen and an effective adjuvant comprising isolated or recombinant YscF, a YscF fragment, trYscF, or homologs thereof. An antigenic composition produced by a process comprising providing a host cell with an expression vector containing a nucleotide sequence encoding YscF, a YscF fragment, trYscF, or YscF homolog capable of acting as an adjuvant; expressing the nucleotide sequence in the host cell to produce the protein; and mixing the collected protein with a suitable excipient. | 05-01-2014 |
| 20140120129 | CHLAMYDIA ANTIGENS - antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as | 05-01-2014 |
| 20140127250 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS - The invention provides proteins from | 05-08-2014 |
| 20140127251 | VACCINES FOR PREVENTION AND TREATMENT OF TUBERCULOSIS - The present invention provides new immunological compositions and vaccines comprising selected | 05-08-2014 |
| 20140127252 | TULAREMIA-TAA/CD40L VACCINE - A Tularemia vaccine proposes to induce antibodies which through their binding to the target proteins of the vaccine strategy will inactivate the proteins essential to mediating the secretory function of the pilus proteins of the “type IV pilus proteins” or Tfp proteins, thereby impairing the formation of the pilus proteins on the surface of the FT which are needed for binding and entry of the FT into macrophages, and will inhibit the secretion of several factors of FT which are necessary for the virulence of the FT, and which are missing in attenuated strains of FT used in current attenuate strain vaccination strategies. The vaccine may be a mixture of DNA plasmids encoding TAA/ecdCD4OL protein vaccines in which the TAA is comprised of fragments of the following Tularemia proteins: Tfp, pilA, pilC, pilT, and pilQ, | 05-08-2014 |
| 20140141029 | CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 05-22-2014 |
| 20140141030 | CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 05-22-2014 |
| 20140141031 | PATHOGENIC BACTERIA - The invention provides novel surface coat proteins of | 05-22-2014 |
| 20140147461 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length | 05-29-2014 |
| 20140154286 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS - The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from | 06-05-2014 |
| 20140161834 | Yersinia spp. Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 06-12-2014 |
| 20140161835 | STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE - The invention relates to an antigenic polypeptide referred to as DivIB and variants thereof, vaccines and immunogenic compositions comprising said polypeptide and the use of the vaccines and/or immunogenic compositions in the treatment and prevention of microbial infections. | 06-12-2014 |
| 20140161836 | CARIOUS TOOTH VACCINE AND PREPARATION METHOD - The present invention provides a vaccine composition for dental caries caused by | 06-12-2014 |
| 20140178423 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 06-26-2014 |
| 20140178424 | IMMUNOGENIC COMPOSITION - The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of | 06-26-2014 |
| 20140178425 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 06-26-2014 |
| 20140186385 | POTOMAC HORSE FEVER ISOLATES - The present invention discloses novel isolates of | 07-03-2014 |
| 20140186386 | METHODS FOR PREVENTING AND TREATING STAPHYLOCOCCUS AUREUS COLONIZATION, INFECTION, AND DISEASE - The invention provided herein relates to a method of preventing a | 07-03-2014 |
| 20140186387 | SIGNAL PEPTIDE FUSION PARTNERS FACILITATING LISTERIAL EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS OF PREPARATION AND USE THEREOF - The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues. | 07-03-2014 |
| 20140193451 | IMMUNOGENIC COMPOSITION - The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and/or PhtD, vaccines comprising the immunogenic compositions and their use in medicine. | 07-10-2014 |
| 20140199339 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST BACTERIA IN THE GENUS STAPHYLOCOCCUS - This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases. | 07-17-2014 |
| 20140205623 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - Vaccine compositions and methods for protecting a mammalian subject against infection with | 07-24-2014 |
| 20140212448 | KLEBSIELLA ANTIGENS - The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from | 07-31-2014 |
| 20140212449 | POLYPEPTIDE-VACCINES FOR BROAD PROTECTION AGAINST HYPERVIRULENT MENINGOCOCCAL LINEAGES - A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET 5 and lineage 3 of | 07-31-2014 |
| 20140212450 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - Vaccine compositions and methods for protecting a mammalian subject against infection with | 07-31-2014 |
| 20140212451 | Lyme Disease Vaccine - Antigenic polypeptides comprising linear immunodominant epitopes of | 07-31-2014 |
| 20140220064 | IMMUNIZING COMPOSITION - The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of | 08-07-2014 |
| 20140220065 | THERAPEUTIC APPLICATION OF S. PYOGENES C-TERMINAL PEPTIDE - A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcus | 08-07-2014 |
| 20140220066 | GROUP A STREPTOCOCCUS MULTIVALENT VACCINE - Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A | 08-07-2014 |
| 20140234363 | POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE - Polypeptides comprising non-typeable | 08-21-2014 |
| 20140234364 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS - The present invention relates to the total chemical synthesis of the monosaccharide 35 | 08-21-2014 |
| 20140242105 | VACCINES FOR CHLAMYDIA - The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus | 08-28-2014 |
| 20140242106 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS - The invention provides proteins from | 08-28-2014 |
| 20140248302 | RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES - A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats. | 09-04-2014 |
| 20140248303 | SYNTHETIC STREPTOCOCCUS PNEUMONIAE VACCINE - Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2 | 09-04-2014 |
| 20140255443 | Nucleic Acid And Amino Acid Sequences Relating To Streptococcus Pneumoniae For Diagnostics And Therapeutics - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection. | 09-11-2014 |
| 20140271700 | COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES - Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of | 09-18-2014 |
| 20140271701 | USE OF MYCOBACTERIUM AVIUM PARATUBERCULOSIS PEPTIDES TO DIAGNOSE TYPE 1 DIABETES - The present invention concerns antibodies recognizing | 09-18-2014 |
| 20140286986 | POLYPEPTIDES HAVING IMMUNOACTIVATING ACTIVITY AND METHODS OF PRODUCING THE SAME - Isolated polypeptides are provided that comprise a cholera toxin B subunit variant having one or more modifications to increase the expression of the polypeptide in a plant cell. Nucleic acids sequences, vectors, and plant cells for expressing the cholera toxin B subunit variant polypeptides are also provided. Further provided are methods for producing the cholera toxin B subunit variant polypeptides that include the steps of transforming a plant cell with a nucleic acid encoding the cholera toxin B subunit variant polypeptides; expressing the variant polypeptides; and purifying the polypeptides. Still further provided are methods of isolating the variant polypeptides that include the steps of obtaining a plant cell expressing the cholera toxin B subunit variant polypeptides; extracting the cholera toxin B subunit variant polypeptides from the plant cell; and purifying the cholera toxin B subunit variant polypeptides. Methods of eliciting an immune response are also provided. | 09-25-2014 |
| 20140294881 | PROTEASES PRODUCING AN ALTERED IMMUNOLOGICAL RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 10-02-2014 |
| 20140294882 | COMPOSITIONS AND METHODS FOR DETECTING, TREATING, AND PROTECTING AGAINST FUSOBACTERIUM INFECTION - The present invention relates to protecting against, treating, and detecting | 10-02-2014 |
| 20140294883 | VACCINE - The present invention is concerned with the development of a vaccine against | 10-02-2014 |
| 20140294884 | MENINGOCOCCUS ADHESINS NADA, APP AND ORF 40 - NadA, App and ORF40 function as adhesins in | 10-02-2014 |
| 20140294885 | HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS - Alternative and improved approaches to the heterologous expression of the proteins of | 10-02-2014 |
| 20140294886 | ISOLATED PROTEIN AND COMPOSITIONS COMPRISING THE PROTEIN - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 10-02-2014 |
| 20140294887 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 10-02-2014 |
| 20140294888 | PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2451 PROTEIN - The present invention relates to methods of inducing an immune response to | 10-02-2014 |
| 20140302083 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES AND NUCLEOTIDES - The present invention relates to isolated | 10-09-2014 |
| 20140302084 | IMMUNOGENIC PROTEIN CONJUGATES AND METHOD FOR MAKING AND USING THE SAME - Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided. In certain aspects, methods for generating an immune response to | 10-09-2014 |
| 20140314801 | VACCINES AND METHODS TO TREAT LYME DISEASE IN DOGS - The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of | 10-23-2014 |
| 20140314802 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 10-23-2014 |
| 20140314803 | COMPOSITIONS AND METHODS RELATED TO P6 - Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM. | 10-23-2014 |
| 20140322256 | Vaccine Candidates Against Johne's Disease - A composition and method for immunizing a mammal infected with | 10-30-2014 |
| 20140335120 | DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - Provided herein are recombinant | 11-13-2014 |
| 20140335121 | FIMBRIAE TYPE OF PROPHYROMONAS GULAE - The present invention has as its object to provide a process for determining the degree of pathogenicity of infecting bacterial strains in the case of canine periodontal disease. | 11-13-2014 |
| 20140341942 | Modified Streptococcus Pneumonia Pneumolysin (PLY) Polypeptides - This disclosure relates to modified | 11-20-2014 |
| 20140341943 | EHRLICHIA EWINGII PROTEINS, NUCLEIC ACIDS, AND METHODS OF THEIR USE - The novel omp-1 gene cluster encoding twenty one | 11-20-2014 |
| 20140341944 | PROTEINS COMPRISING MRSA PBP2A AND FRAGMENTS THEREOF, NUCLEIC ACIDS ENCODING THE SAME, AND COMPOSITIONS AND THEIR USE TO PREVENT AND TREAT MRSA INFECTIONS - Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual. | 11-20-2014 |
| 20140348867 | Isolated Brachyspira and Methods and Compositions for Expanding and Isolating Brachyspira - The disclosure provides isolated—, compositions comprising—and methods of culturing —a | 11-27-2014 |
| 20140348868 | COMPOSITIONS COMPRISING PNEUMOCOCCAL ANTIGENS - Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens. | 11-27-2014 |
| 20140348869 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES - The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH. | 11-27-2014 |
| 20140356389 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI - Disclosed herein are various open reading frames from a strain of | 12-04-2014 |
| 20140356390 | MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS - Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed. | 12-04-2014 |
| 20140363461 | ADJUVANTED FORMULATIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The efficacy of | 12-11-2014 |
| 20140363462 | HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS - Alternative and improved approaches to the heterologous expression of the proteins of | 12-11-2014 |
| 20140377300 | Tuberculosis Compositions And Methods Of Using The Same - The present disclosure provides fusion proteins comprising | 12-25-2014 |
| 20150010591 | CHLAMYDIA ANTIGEN COMPOSITIONS AND USES THEREOF - The present invention provides in part peptides and polypeptides derived from | 01-08-2015 |
| 20150017198 | MUTATED AND BACTERIOPHAGE T4 NANOPARTICLE ARRAYED F1-V IMMUNOGENS FROM YERSINIA PESTIS AS NEXT GENERATION PLAGUE VACCINES - Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH | 01-15-2015 |
| 20150017199 | CHOLERA TOXIN CHIMERA AND ITS USE AS A STAPH VACCINE - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of | 01-15-2015 |
| 20150023997 | COMPOSITIONS, METHODS AND THERAPIES FOR ADMINISTERING ANTIGEN PEPTIDE - The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with | 01-22-2015 |
| 20150023998 | Stable Anthrax Vaccine Formulations - Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection. | 01-22-2015 |
| 20150023999 | Novel Targets of Acinetobacter Baumannii - The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as | 01-22-2015 |
| 20150024000 | MULTIVALENT VACCINE PROTECTION FROM STAPHYLOCOCCUS AUREUS INFECTION - Vaccine formulations effective against | 01-22-2015 |
| 20150030624 | Campylobacter Immunogenic Compositions and Uses Thereof - The present invention provides immunogenic compositions against | 01-29-2015 |
| 20150030625 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 01-29-2015 |
| 20150044249 | POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian | 02-12-2015 |
| 20150044250 | VACCINES AGAINST CLOSTRIDIUM DIFFICILE COMPRISING RECOMBINANT TOXINS - The present invention relates to recombinant | 02-12-2015 |
| 20150050311 | NOVEL METHOD FOR THE PREPARATION OF A STRAIN-ADAPTED VACCINE - The present invention relates to a method for the preparation of a strain-adapted vaccine specific for a bacterial strain, comprising the steps of: (a) genetically engineering a bacterial strain obtained from a subject, wherein said genetic engineering comprises introducing a nucleic acid molecule encoding a fusion protein, wherein the fusion protein comprises a bacterial membrane protein fused to at least one affinity tag, (b) growing the genetically engineered bacterial strain obtained in step (a) in solution, (c) isolating membrane vesicles from the growth culture of step (b) by affinity purification using the affinity tag, and (d) formulating the membrane vesicles isolated in step (c) into a strain-adapted vaccine. The present invention further relates to a nucleic acid molecule encoding a fusion protein comprising a bacterial membrane protein fused to at least one affinity tag and a kit comprising said fusion protein. | 02-19-2015 |
| 20150050312 | BACTERIAL VACCINE - The disclosure relates to a composition comprising one, two or more immunogenic bacterial polypeptides and multi-valent and monovalent vaccine compositions comprising the immunogenic bacterial polypeptides. | 02-19-2015 |
| 20150056238 | ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF - This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of | 02-26-2015 |
| 20150056239 | FUSED ANTIGEN VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE - is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in | 02-26-2015 |
| 20150056240 | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIANTS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 02-26-2015 |
| 20150056241 | Compositions And Methods For Immunodominant Antigens - Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens ( | 02-26-2015 |
| 20150056242 | NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS - Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as | 02-26-2015 |
| 20150064207 | EPSILON TOXIN EPITOPES FROM CLOSTRIDIUM PERFRINGENS WITH REDUCED TOXICITY - There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by | 03-05-2015 |
| 20150064208 | POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammaliran | 03-05-2015 |
| 20150071956 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E, pE), a virnlence factor, which can be detected in | 03-12-2015 |
| 20150071957 | POLYPEPTIDE AND IMMUNE MODULATION - The present invention relates to | 03-12-2015 |
| 20150071958 | IMMUNOLOGICAL COMPOSITION FOR CLOSTRIDIUM DIFFICILE - The invention relates to methods and compositions for treating or inhibiting infection of | 03-12-2015 |
| 20150071959 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF - In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human. | 03-12-2015 |
| 20150079124 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 03-19-2015 |
| 20150079125 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 03-19-2015 |
| 20150086581 | Fast Diagnosis and Personalized Treatment for Acne - Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof. | 03-26-2015 |
| 20150086582 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 03-26-2015 |
| 20150093407 | TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION - The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms ( | 04-02-2015 |
| 20150098961 | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits - The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic | 04-09-2015 |
| 20150110829 | MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING CONJUGATES - Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4° C. | 04-23-2015 |
| 20150110830 | DETOXIFIED ESCHERICHIA COLI IMMUNOGENS - Detoxified variants of the pathogenic | 04-23-2015 |
| 20150118261 | ESCHERICHIA COLI VACCINE COMBINATION - The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto. | 04-30-2015 |
| 20150118262 | Haemophilus Influenzae Type IV PILI - The invention described herein relates to a | 04-30-2015 |
| 20150125481 | Immunogenic Composition - The present invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain. In a further embodiment, the invention discloses an immunogenic composition comprising at least two different staphylococcal polypeptides, each comprising an IgG binding domain. | 05-07-2015 |
| 20150132333 | CLOSTRIDIUM DIFFICILE TOXIN-BASED VACCINE - The present invention relates to recombinant fragments of | 05-14-2015 |
| 20150132334 | METHODS FOR DISPLAYING POLYPEPTIDES AND USES THEREOF - Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines. | 05-14-2015 |
| 20150132335 | BACTERIAL VACCINE COMPONENTS AND USES THEREOF - Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the | 05-14-2015 |
| 20150132336 | IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from | 05-14-2015 |
| 20150132337 | COMBINATION GAS VACCINES AND THERAPEUTICS - Compositions useful for reducing the risk of, preventing, and/or treating | 05-14-2015 |
| 20150140026 | INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM - The present disclosure relates to surface proteins of | 05-21-2015 |
| 20150290311 | M. TUBERCULOSIS VACCINES - The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by | 10-15-2015 |
| 20150290312 | GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis - The present invention generally provides methods and compositions for eliciting an immune response against | 10-15-2015 |
| 20150299272 | RECOMBINANT POLYPEPTIDE - The invention provides a chaperone/usher family polymer comprising at least one chaperone/usher family polypeptide monomer, wherein said at least one chaperone/usher family polypeptide monomer comprises an exogenous bioactive sequence. | 10-22-2015 |
| 20150306200 | VECTORS FOR TRANSFORMING MYCOPLASMA HYOPNEUMONIAE, TRANSFORMED M. HYOPNEUMONIAE STRAINS, AND USE THEREOF - The present invention relates to mutant strains of | 10-29-2015 |
| 20150306201 | NOVEL METHOD FOR TREATING H.PYLORI INFECTIONS - The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ.ID.No. 1, whereby such region is defined by
| 10-29-2015 |
| 20150307563 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 10-29-2015 |
| 20150313985 | IMMUNOGENIC COMPOSITION COMPRISING ELEMENTS OF C. DIFFICILE CDTB AND/OR CDTA PROTEINS - The present invention relates to immunogenic compositions comprising isolated | 11-05-2015 |
| 20150315248 | CLOSTRIDIUM DIFFICILE POLYPEPTIDES AS VACCINE - The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating a | 11-05-2015 |
| 20150315255 | IMMUNE MODULATOR FOR IMMUNOTHERAPY AND VACCINE FORMULATION - A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF- | 11-05-2015 |
| 20150320851 | PNEUMOCOCCAL VACCINE CONTAINING PNEUMOCOCCAL SURFACE PROTEIN A - A pneumococcal vaccine comprising a fusion protein at least comprising a full-length family 1 pneumococcal surface protein A (PspA) or a fragment thereof, and a full-length family 2 PspA or a fragment thereof, in particular any one of the following fusion proteins (1) to (3):
| 11-12-2015 |
| 20150322116 | PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS - An effective | 11-12-2015 |
| 20150323531 | Compositions and Methods for Detection of Antibodies Specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl) - The invention provides methods and compositions for the detection and treatment of | 11-12-2015 |
| 20150328301 | GLYCOCONJUGATE VACCINES - The disclosure relates to a glycoconjugate vaccine conferring protection against | 11-19-2015 |
| 20150335723 | Group A Streptococcus Pharmaceutical Compositions and Methods Thereof - Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A | 11-26-2015 |
| 20150335724 | IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 11-26-2015 |
| 20150335752 | Temperature Stable Vaccine Formulations - Formulations of vaccine antigen, such as anthrax protective antigen, are provided that are stable after undergoing freeze and thaw conditions. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection. | 11-26-2015 |
| 20150343043 | Subunit Immersion Vaccines for Fish - The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is | 12-03-2015 |
| 20150343044 | A vaccine for treatment or prevention of Burkholderia infection in a mammal - An agent for use in a vaccine therapy to prevent or treat a | 12-03-2015 |
| 20150343047 | COMPOSITIONS AND METHODS FOR TREATMENT OF CERVICAL DYSPLASIA - The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant | 12-03-2015 |
| 20150343049 | Vaccine - The invention relates to vaccines, and particularly to vaccines active against pathogenic bacteria including | 12-03-2015 |
| 20150344530 | Synthetic Peptides as Carriers for Conjugation with Polysaccharides - The invention is directed to compositions and methods for the manufacture and administration of vaccines wherein the peptide comprises at least 28 amino acid residues of pneumococcal surface adhesion A and, in particular compositions, methods and tools for the conjugation of peptides with polysaccharides and other chemical agents in the formulation of vaccines. | 12-03-2015 |
| 20150344531 | MEDICAMENT FOR LCT POISONING - The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular | 12-03-2015 |
| 20150353610 | NOVEL RECOMBINANT OUTER MEMBRANE PROTEINS FROM BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF - The present invention relates generally to the field of diarrhoeal diseases caused by intestinal spirochaetes. Specifically, the invention relates to the prevention and/or treatment of infections with | 12-10-2015 |
| 20150359870 | IMMUNOLOGICALLY ACTIVE COMPOSITIONS - This invention provides a microparticle carrier system comprising of one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other bioactive substances with or without targeting molecules attached. In addition, the invention also provides immune modulatory compositions and methods of eliciting protective immune responses both in uninfected and infected hosts as well as the induction of immune tolerance. | 12-17-2015 |
| 20150366959 | ANTI-MYCOPLASMA SPP. SUBUNIT VACCINE - Provided in the present invention are anti- | 12-24-2015 |
| 20150366963 | METHODS FOR ENHANCING AN IMMUNE RESPONSE TO AN ANTIGEN - Provided are methods and kits for enhancing an immune response to an antigen in an individual comprising administering to the individual an effective amount of (a) LT-IIb or (b) LT-IIb(T13I) enterotoxin, and (c) an antigen, whereby the LT-IIb or LT-IIb(T13I) enterotoxin acts as an adjuvant to enhance the generation of antigen specific neutralizing antibodies. | 12-24-2015 |
| 20150374811 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE - The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumoccocus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a thereapeutic immune response to an infected individual. | 12-31-2015 |
| 20150376242 | Modified Streptococcus Pneumoniae Pneumolysin (PLY) Polypeptides - This disclosure relates to immunogenic compositions comprising mutant | 12-31-2015 |
| 20160008450 | COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE | 01-14-2016 |
| 20160015806 | Genetically Detoxified Pertussis that Maintains Intrinsic Adjuvant Activity - The invention is directed to a method for the production of a | 01-21-2016 |
| 20160017006 | IMMUNOGENIC FUSION POLYPEPTIDES - In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against | 01-21-2016 |
| 20160017007 | VIBRO-BASED DELIVERY SYSTEM AND IMMUNE SUPPRESSION - Embodiments described are immunosuppressant therapeutics and compositions comprising a Vop protein derived from | 01-21-2016 |
| 20160022795 | Prevention and Treatment of Mycobacterium Infection - The invention relates to the identification of antigens, including | 01-28-2016 |
| 20160022796 | Synthetic Immunogens For Prophylaxis Or Treatment Of Tuberculosis - Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed. | 01-28-2016 |
| 20160022799 | METHODS AND COMPOSITIONS EMPLOYING IMMUNOGENIC FUSION PROTEINS - Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumo-coccal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one poly-peptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. | 01-28-2016 |
| 20160024157 | HAEMOPHILUS INFLUENZAE TYPE B - Polypeptides comprising various amino acid sequences derived from | 01-28-2016 |
| 20160024173 | NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME - The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest. | 01-28-2016 |
| 20160030543 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF - In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from | 02-04-2016 |
| 20160030544 | IMMUNOGENIC COMPOSITION TO NEISSERIA - The present invention provides an immunogenic composition capable of eliciting an immune response when administered to a human or non-human animal, wherein the composition comprises an isolated protein with one or more of the following properties: i) about 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or more percent sequence identity to the protein of SEQ ID No: 1 or a fragment, derivative or analog thereof; ii) is a modified factor H binding protein, wherein the factor H binding protein has been modified at least at the position equivalent to position 318 as defined in FIG. | 02-04-2016 |
| 20160030545 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 02-04-2016 |
| 20160030546 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 02-04-2016 |
| 20160038581 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO ENTERIC PATHOGENS - Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide. | 02-11-2016 |
| 20160039887 | MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870. | 02-11-2016 |
| 20160045588 | CHLAMYDIA ANTIGEN COMPOSITIONS AND USES THEREOF - The present invention provides in part fusion proteins derived from | 02-18-2016 |
| 20160051655 | YERSINIA SPP. POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 02-25-2016 |
| 20160051656 | BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE | 02-25-2016 |
| 20160051658 | NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria | 02-25-2016 |
| 20160052974 | NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF - Novel polynucleotide and amino acids of | 02-25-2016 |
| 20160052975 | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits - The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic | 02-25-2016 |
| 20160067326 | MUTANT BACTERIA FOR PRODUCTION OF GENERALIZED MODULES FOR MRMBRANE ANTIGENS - Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable | 03-10-2016 |
| 20160067327 | OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of | 03-10-2016 |
| 20160074492 | Oral Vaccine For Borrelia - The present invention relates to vaccines for control of | 03-17-2016 |
| 20160074493 | IMMUNOGENIC COMPOSITIONS CONTAINING ESCHERICHIA COLI H7 FLAGELLA AND METHODS OF USE THEREOF - Immunogenic compositions containing | 03-17-2016 |
| 20160074496 | CLOSTRIDIUM DIFFICILE VACCINE AND METHODS OF USE - Embodiments of the present disclosure include vaccine compositions comprising a TcdB toxin or toxoid derived therefrom. The TcdB toxin may be derived from a hypervirulent strain of | 03-17-2016 |
| 20160074497 | STAPHYLOCOCCUS LIVE CELL VACCINES - protein A variants, defective in immunoglobulin binding, elicit protective immunity against staphylococcal disease. The present invention includes methods for preventing or ameliorating staphylococcal infections, particularly hospital acquired nosocomial infections. As such, the invention contemplates vaccines for use in both active and passive immunization embodiments. In certain embodiments the vaccine is an isolated recombinant staphylococcal bacteria that expresses a variant Protein A (SpA variant) comprising (a) at least one amino acid substitution that disrupts Fc binding and (b) at least a second amino acid substitution that disrupts VH3 binding variant in at least one of SpA A, B, C, D, and/or E domains. | 03-17-2016 |
| 20160082098 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 03-24-2016 |
| 20160083435 | VACCINES AND METHODS TO TREAT LYME DISEASE IN DOGS - The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of | 03-24-2016 |
| 20160083437 | COMPOSITION COMPRISING RECOMBINANT FUSION PROTEIN OF PATHOGENIC ANTIGEN PROTEIN AND FLAGELLIN OF VIBRIO VULNIFICUS FOR PREVENTING, ALLEVIATING, OR TREATING AGING - The present invention relates to a composition for preventing, improving, or treating aging, wherein the composition comprises a recombinant protein of flagellin, which is the constituent of | 03-24-2016 |
| 20160101172 | IMMUNIZATION TO PROTECT AGAINST ADVERSE CARDIAC EVENTS RELATING TO PNEUMOCOCCAL INFECTION - In some aspects, provided herein are methods and compositions for treating or preventing adverse cardiac events in a patient who has suffered an invasive pneumococcal infection or is at risk of such an infection. The compositions include fusion proteins comprising a CbpA polypeptide or active fragment or variant thereof and optionally a T cell epitope (TCE) and a third immunogenic polypeptide from a bacteria. | 04-14-2016 |
| 20160106826 | VACCINES AGAINST PATHOGENIC ESCHERICHIA COLI AND METHODS OF USING THE SAME - Provided herein are compositions and methods for vaccinating against infection with pathogenic | 04-21-2016 |
| 20160114020 | Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax - The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of | 04-28-2016 |
| 20160114021 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZA PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in | 04-28-2016 |
| 20160114051 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS - The present invention relates to an immunogenic and a non-toxic glycoconjugate comprising | 04-28-2016 |
| 20160120969 | COMBINATION VACCINE - The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides. | 05-05-2016 |
| 20160129100 | IMMUNGENIC TP0751 FRAGMENTS - The present application provides methods of stimulating an immune response, such as a protective immune response against | 05-12-2016 |
| 20160129101 | IMMUNOGENIC COMPOSITION FOR USE IN THERAPY - This application relates to immunogenic compositions comprising a | 05-12-2016 |
| 20160132631 | BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING - This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes. | 05-12-2016 |
| 20160136255 | VACCINATION WITH RECOMBINANT MYCOBACTERIUM TUBERCULOSIS PknD ATTENUATES BACTERIAL DISSEMINATION TO THE BRAIN - Vaccines comprising | 05-19-2016 |
| 20160136285 | AN ISOLATED IMMUNOGENIC BACTERIAL ANTIGEN AND ITS USE IN THE PREVENTION AND TREATMENT OF INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA - The subject of the present invention is an isolated antigen being an immunogenic form of the common enterobacterial antigen (ECA) of Gram-negative bacteria of the family Enterobacteriaceae: ECA combined with lipopolysaccharide (ECA | 05-19-2016 |
| 20160136293 | STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES - Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS. In various embodiments, the disclosed compositions are suitable for delivery into a cell (i) the expression product of a gene of interest and/or (ii) novel peptides or polynucleotides to regulate gene function. | 05-19-2016 |
| 20160137702 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 05-19-2016 |
| 20160138004 | Amino Acid Sequence Presenting Fusion Polypeptide And Its Use - Herein is reported a fusion polypeptide according to formula I | 05-19-2016 |
| 20160144015 | BORDETELLA OUTER-MEMBRANE PROTEIN ANTIGENS AND METHODS OF MAKING AND USING THE SAME - An isolated protein or peptide selected from the group consisting of | 05-26-2016 |
| 20160151476 | COMBINATION NEISSERIAL COMPOSITIONS | 06-02-2016 |
| 20160158335 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 06-09-2016 |
| 20160158336 | Attenuated Mannheimia haemolytica Vaccines and Methods of Making and Use - The present invention provides attenuated | 06-09-2016 |
| 20160158337 | CHLAMYDIA ANTIGENS - The invention provides | 06-09-2016 |
| 20160159865 | Non-Naturally Occurring Factor H Binding Proteins (fHbp) and Methods of Use Thereof - Non-naturally occurring factor H binding proteins derived from variant 3 fHbp that can elicit antibodies that are bactericidal for at least one strain of | 06-09-2016 |
| 20160166671 | Clostridium Difficile Compositions and Methods of Use | 06-16-2016 |
| 20160166673 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS | 06-16-2016 |
| 20160166674 | VACCINES FOR SEROGROUP X MENINGOCOCCUS | 06-16-2016 |
| 20160168208 | Peptides derived from Campylobacter jejuni and their use in vaccination | 06-16-2016 |
| 20160175418 | Ureaplasma Vaccine and Antibodies | 06-23-2016 |
| 20160175419 | POLYMER PARTICLES AND USES THEROF | 06-23-2016 |
| 20160175422 | COMBINATION NEISSERIAL COMPOSITIONS | 06-23-2016 |
| 20160175424 | Haemophilus Influenzae Type IV PILI | 06-23-2016 |
| 20160184420 | Novel Compositions and Methods - The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 06-30-2016 |
| 20160184422 | Campylobacter Immunogenic Compositions and Uses Thereof - The present invention provides immunogenic compositions against | 06-30-2016 |
| 20160185827 | VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS - The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2AP) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type IV pilus-associated proteins and the β2AP. | 06-30-2016 |
| 20160185829 | Toxoid Peptides Derived from Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions Thereof - The present disclosure provides immunogenic compositions useful in prevention and treatment of | 06-30-2016 |
| 20160193319 | Flagellin Fusion Proteins and Use Thereof to Induce Immune Responses Against Pseudomonas aeruginosa | 07-07-2016 |
| 20160194362 | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits | 07-07-2016 |
| 20160194363 | Compositions and Methods Related to Protein A (SpA) Variants | 07-07-2016 |
| 20160199476 | DEVELOPMENTS IN MENINGOCOCCAL OUTER MEMBRANE VESICLES | 07-14-2016 |
| 20160250313 | FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A | 09-01-2016 |
| 20160250314 | COMPOSITIONS AND METHODS FOR DETECTING, TREATING, AND PROTECTING AGAINST FUSOBACTERIUM INFECTION | 09-01-2016 |
| 20160375119 | VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS - The invention relates to a novel use of a | 12-29-2016 |
| 20170234871 | MYCOBACTERIUM TUBERCULOSIS PROTEINS | 08-17-2017 |
| 20180021450 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | 01-25-2018 |
| 20180022783 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF | 01-25-2018 |
